来曲唑治疗多囊卵巢综合征的系统评价

 目的 评价来曲唑对多囊卵巢综合征患者促排卵治疗的有效性和安全性。方法 检索Pubmed、Embase、Cochrane系统评价和临床试验数据库，CNKI，收集相关随机对照试验，经质量评价后用RevMan5.1软件进行Meta分析。结果 共纳入6项随机对照试验，均为英文文献。Meta分析结果显示在妊娠率、排卵率、流产率及不良事件发生率方面来曲唑和枸橼酸氯米芬之间的差异无统计学意义（1.15[0.86，1.54]，1.11[0.91，1.34]，1.45[0.52，4.08]，0，[-0.01，0.01]）；对于BMI＜30的多囊卵巢综合征患者，来曲唑的治疗效果明显好于枸橼酸氯米芬[妊娠率：RR=1.64,95%CI（1.08，2.50）]。结论 对于BMI＜30的多囊卵巢综合征患者，来曲唑可以取代枸橼酸氯米芬成为一线促排卵药物；而对于BMI＞30的多囊卵巢综合征患者，建议仍采用指南方案，先行生活方式的改善。来曲唑能否代替枸橼酸氯米芬成为一线促排卵药物仍需大规模的，设计良好的随机对照试验来验证。

Letrozole for Ovulation Induction in Women with Polycystic Ovarian Syndrome: A Systematic Analysis

OBJECTIVE To assess the effectiveness and safety of letrozole(LE) for ovulation induction in women with PCOS.METHODS Pubmed,Embase,CNKI,and the Cochrane Library were searched.Randomized controlled trials of letrozole for ovulation induction in women with PCOS were collected.The quality of the retrieved trials was assessed,and meta-analyses were conducted using RevMan software 5.1.RESULTS Six RCTs were included,all of which were published in English.The results of Meta-analyses showed that there were no sign...